117976-89-3

117976-89-3 structure

Name: Rabeprazole
Chemical Name: rabeprazole
CAS Number: 117976-89-3
Molecular Formula: C₁₈H₂₁N₃O₃S
Molecular Weight: 359.443
Catalog: API Digestive system medication Acid and gastric mucosal protective drugs
Create Date: 2018-05-16 08:00:00
Modify Date: 2024-01-02 18:41:45
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.Target: Proton PumpRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.

Name	rabeprazole
Synonyms	Rebeprazole 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole Pariprazole 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole 2-({[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl}sulfinyl)-1H-benzimidazole MFCD00868879 Rabeprazole 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]- 2-({[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole

Description	Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.Target: Proton PumpRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump Research Areas >> Inflammation/Immunology
References	[1]. http://www.drugbank.ca/drugs/DB01129

117977-21-6

~90%

117976-89-3

Literature: US2009/5570 A1, ; Page/Page column 3-4 ;

1080503-70-3

1080503-68-9

~90%

117976-89-3

Literature: EP1992619 A1, ; Page/Page column 16 ;

924663-40-1

~5%

117976-89-3

Literature: US2007/249662 A1, ; Page/Page column 5 ;

408332-88-7

117977-21-6

~49%

117976-89-3

Literature: US5948789 A1, ; US 5948789 A

13811-71-7

117977-21-6

~59%

117976-89-3

Literature: US5948789 A1, ; US 5948789 A

924663-38-7

117976-89-3

Literature: EP1921075 A2, ; Page/Page column 8 ;

117977-21-6

~75%

117976-89-3

117976-47-3

Literature: WO2006/24890 A1, ; Page/Page column 6-7 ;

937-14-4

117977-21-6

117976-89-3

Literature: EP1818331 A1, ; Page/Page column 6 ;